Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China

被引：0
作者：
Bin Wu
Jinfang Shen
Huafeng Cheng
机构：
[1] Renji Hospital,Department of Pharmacy Clinical Outcomes and Economics Group
[2] affiliated with the School of Medicine,undefined
[3] Shanghai Jiaotong University,undefined
来源：
BMC Health Services Research | / 12卷
关键词：
Hepatitis B; Lamivudine resistance; Rescue therapy; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 266 条
  • [1] Lee WM(1997)Hepatitis B virus infection N Engl J Med 337 1733-1745
  • [2] Ganem D(2004)Hepatitis B virus infection–natural history and clinical consequences N Engl J Med 350 1118-1129
  • [3] Prince AM(2009)National Institutes of Health Consensus Development Conference Statement: management of hepatitis B Ann Intern Med 150 104-110
  • [4] Sorrell MF(2009)Benefits and risks of nucleoside analog therapy for hepatitis B Hepatology 49 S112-S121
  • [5] Belongia EA(2010)Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis Value Health 13 592-600
  • [6] Costa J(2010)Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon Liver Int 30 657-668
  • [7] Gareen IF(2004)Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 19 1276-1282
  • [8] Grem JL(2009)Antiviral resistance and hepatitis B therapy Hepatology 49 S174-S184
  • [9] Inadomi JM(2010)Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B Antivir Ther 15 235-241
  • [10] Kern ER(2009)Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus Virol J 6 163-796
12345678910